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Purpose: The antiphospholipid antibodies (APL)--anticardiolipin antibodies (ACL) and 
lupus anticoagulant (LA)--are widely believed to be associated with decreased lower 
extremity bypass graft patency rates. To date, no prospective cohort study has confirmed 
this assumption. A prospective comparison of the result of infrainguinal revascularization 
procedures performed since 1990 in patients with and without APL forms the basis of this 
report. 
Methods: Patients who underwent elective infrainguinal bypass procedures from 1990 to 
1994 were evaluated for hypercoagulable states (ACL, LA, protein C, protein S, and 
antithrombin III). Patient data were prospectively entered in a computerized vascular 
registry, and postoperative follow-up was maintained for life. Graft patency, limb salvage, 
and patient survival rates were calculated by life-table methods. 
Results: Three hundred twenty-seven lower extremity bypass grafting procedures were 
performed in262 patients. APLs were present in 83 patients (32%); 70 patients (84%) had 
ACLs only, 11 patients (13%) had LA only, and two patients (3%) had both ACLs and LA. 
There was no significant difference between APL-positive and APL-negative patients with 
respect o demographics, associated medical conditions, indication for operations, and 
type of procedures performed. More patients who had APLs had warfarin treatment after 
surgery (43% vs 24%, p = 0.002). Life table 4-year primary patency rates howed minimal 
difference (APL-positive, 43%; APL-negative, 59%; p = 0.087), and no significant 
difference was noted in assisted primary patency rates (APL positive, 72%; APL negative, 
73%; p = NS), limb salvage rates (APL positive, 79%; APL negative, 88%; p = NS), and 
patient survival rates (APL positive, 67%; APL negative, 66%; p = NS). 
Conclusions: APLs were found in a surprising one third of the patients who underwent leg 
bypass grafting procedures. The majority of APLs identified were ACLs (87%). There was 
minimal difference in graft primary patency rates, and no difference in assisted primary 
patency, limb salvage, and survival rates between patients with and without APLs who 
underwent leg bypass grafting procedures. The extreme morbidity rate associated with 
APLs in previous reports is not confirmed by this prospective study. APLs should not be 
regarded as a contraindication to indicated leg bypass grafting procedures. (J Vase Surg 
1996;24:524-33.) 
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First described in patients who had systemic lupus 
erythematosus and thrombosis, 1 autoantibodies to 
phospholipid (APL) subsequently have been associ- 
ated with venous thrombosis, 2'3 coronary artery by- 
pass thrombosis, 4 myocardial infarction, s stroke, 6-s 
transient cerebral ischemic attacks, 9 and peripheral 
arterial occlusive disease. 1°-1s These repeatedly con- 
firmed observations have led to acceptance of the 
presence of APL as being diagnostic of an hyperco- 
agulable state. Multiple previous case reports have 
described patients who had peripheral arterial occlu- 
sive disease and APL, frequently with rapidly progres- 
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sive disease, and early or repeated failure of recon- 
structive surgery .  1°32,14,1~'17,18 
In a previously reported cross-sectional study of 
general vascular surgery patients, we found APLs in 
26.4%, establishing APLs as the most frequent hyper- 
coagulable state encountered in patients who un- 
dergo vascular procedures. 16In that study, APLs were 
significantly associated with multiple leg procedures 
and with a history of rapid failure of leg procedures. 
Because all previous reports that associated APL and 
leg arterial disease are either case reports or retrospec- 
tive studies, there is need for information regarding 
the effect of APL on prognosis after leg revascular- 
ization, information that can most reliably be ob- 
tained from a prospective study. 
Since 1990, all patients who have undergone 
arterial vascular surgery at our institution have under- 
gone screening for the presence of hypercoagulable 
states, including APL. A comparison of prospectively 
obtained results of infrainguinal revascularization in 
patients who have APL (APL positive), compared 
with the results of infrainguinal revascularization in 
patients without APL (APL negative) forms the basis 
for this report. 
PATIENTS AND M~ETHODS 
From January 1,1990, to December 31, 1994, all 
patients who were admitted to the Vascular Surgery 
Service at Oregon Health Sciences University for 
elective leg revascularization procedures were evalu- 
ated for the presence of hypercoagulable states. Pa- 
tients who underwent emergency surgery to treat 
acute thromboembolic events and patients who were 
already receiving warfarin anticoagulation therapy 
were not included in this study. The laboratory studies 
obtained included a complete blood count with 
platelet count, prothrombin time, activated partial 
thromboplastin time, protein C activity, free protein S 
antigen, and antithrombin III activity. These studies 
were performed by standard laboratory methods. In 
addition, tests for anticardiolipin antibodies and lupus 
inhibitors were performed in all patients. Specific 
details of the test procedures have been described. 16
Patients were considered to have a positive anticar- 
diolipin antibody test if their test result was greater 
than three standard eviations greater than normal 
control evels for immunoglobulin G (IgG), immu- 
noglobulin M (IgM), or immunoglobulin A (IgA). 
Tests for presence of Lupus inhibitors were reported 
as positive, negative, or equivocal. Only positive 
results were considered significant. 
All patients underwent surgical revascularization 
of their legs according to principles published from 
our service for leg arterial occlusive disease. ~9-22 The 
principal points were the use of multiple operating 
teams to simultaneously harvest and prepare the vein 
and expose proximal and distal anastomotic sites, the 
use of the most distal proximal anastomotic site 
possible, the use ofvenectomy and venovenostomy to 
achieve ahigh quality conduits, and anatomic tunnel- 
ing of the bypass. Ipsilateral greater saphenous vein 
was the conduit of choice, followed by contralateral 
greater saphenous vein and arm veins. Bypasses were 
routinely assessed uring surgery with continuous- 
wave Doppler scans. Completion angiographic scans 
were undertaken when the continuous-wave Doppler 
examination suggested a technical problem. 
Results of the hypercoagulable agent screen were 
not available at the time of surgery and thus did not 
influence perioperative decisionmaking with regard 
to the procedures performed or use ofperioperative 
antithrombotic agents. All patients received systemic 
heparin during periods of surgical arterial occlusion. 
All patients received aspirin before and after surgery 
(325 mg/day). Patients who had hypercoagulable 
states received warfarin therapy after surgery unless 
contraindications were present. Some patients who 
did not have hypercoagulable states also received 
warfarin therapy for other indications (atrial fibrilla- 
tion, prosthetic ardiac valves, venous thrombosis, 
multiple arterial thromboses). 
Postoperative examinations were performed every 
3 months for 1 year, andthen every 6 months for life. 
Bypass graft surveillance included ankle-brachial in- 
dex (ABI) and duplex scanning-determined graft 
flow velocity. Patients who had a graft flow velocity 
less than 45 cm/sec or greater than 200 cm/sec, or 
who had a decrease in ABI greater than 0.15 from 
postoperative ABI, underwent arteriographic evalua- 
tion. Lesions of >60% diameter eduction as deter- 
mined by arteriographic scan underwent graft re- 
vision. 
The following information was recorded in our 
vascular surgery database (DataEase, Trumbull, 
Conn.): demographic nformation; medical history, 
including symptomatic coronary artery disease, dia- 
betes, hypertension, renal failure, hyperlipidemia, 
antithrombotic therapy, tobacco use, and vascular 
surgery history; and operative data, including proce- 
dure, indication for procedure, and perioperative 
complications. 
At each follow-up visit, primary patency, assisted 
primary patency, limb salvage, and survival status were 
entered into our vascular surgery database. Demo- 
graphic factors, medical history parameters, and op- 
erative data were examined with reference to associa- 
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Table I. Patient characteristics ofstudy group versus nonstudy group 
Characteristics Study group (262patients) Non-study group (45patients) p (~2) 
Age 67.9 yr 67.2 yr NS 
Male :female 55% :45% 64% : 36% NS 
Diabetes 43.5% 44.4% NS 
Heart disease 63.4% 62.2% NS 
Hypertension 68.3% 73.3% NS 
Renal failure 12.2% 22.2% NS 
Hyperlipidemia 32.4% 40.0% NS 
Smoking history 74.4% 68.9% NS 
Warfarin therapy 29.8% 20.0% NS 
Previous vascular surgery 68.1% 69.0% NS 
Previous failed bypass 48.3% 52.1% NS 
Limb salvage indication 90.5% 93.2% NS 
Table II. Characteristics ofpatients with and without antiphospholipid antibodies 
Characteristics APL-positive (83patients) APL-negative (178patients) p (~2) 
Age 66.4 yr 67.2 yr NS 
Male :female 49% : 51% 57% :43% NS 
Diabetes 35.7% 47.2% NS 
Heart disease 72.6% 60.0% NS 
Hypertension 71.4% 66.9% NS 
Renal failure 14.3% 11.2% NS 
Hyperlipidemia 34.5% 31.3% NS 
Smoking history 79.8% 71.9% NS 
Warfarin therapy 42.9% 23.6% p = 0.002 
Previous vascular surgery 74.5% 64.8% NS 
Previous failed bypass 49.1% 48.0% NS 
tion with the presence or absence ofhypercoagulable 
states with g2 analysis. Life-table analysis was used to 
evaluate primary patency, assisted primary patency, 
limb salvage, and survival rates for patients with and 
without hypercoagulable states. Life tables were com- 
pared with the log-rank test. Definitions and methods 
were according to reporting standards suggested by 
the Society for Vascular Surgery and International 
Society for Cardiovascular Surgery for lower extrem- 
ity ischemiaY 
RESULTS 
During the study period, 307 patients underwent 
386 elective lower extremity revascularization proce- 
dures for leg ischemia. Laboratory tests to detect he 
presence of a hypercoagnlable state were obtained in 
262 patients (85%), who underwent 327 leg bypass 
procedures. The reasons for not obtaining the hyper- 
coagulable screening laboratory studies were omis- 
sion of test order or inadequate laboratory specimen. 
Patient characteristics, indication for procedure, pro- 
cedure performed, and conduits used were no differ- 
ent between the patient cohort that did and the 
cohort that did not undergo hypercoagulable state 
evaluation (Table I). The 45 patients who did not 
have complete hypercoagulable state screening were 
excluded from further analysis in this study. 
Eighty-four patients (32%)who underwent 102 
leg bypass procedures had hypercoagulable states. 
One patient had antithrombin III deficiency and was 
excluded from further analysis in this study. None of 
the patients had protein C or protein S deficiency. The 
other 83 patients had APL: 70 patients (84%) had 
anticardiolipin antibodies only, 11 patients (13%) had 
lupus anticoagulant only, and two patients (3%) had 
both anficardiolipin antibodies and lupus anticoagu- 
lant. Thus of the 84 patients who had hypercoagu- 
lable states, 83 (99%) had file hypercoagulable state as 
a result of the presence of APL (anticardiolipin 
antibody or lupus anticoagulant). 
The demographics and patient characteristics of
patients with and without APL are shown in Table II. 
APL-positive patients had postoperative warfarin 
therapy nearly twice as often as APL-negafive patients 
(p = 0.002). All the other parameters were similar 
between APL-positive and APL-negative patients. 
There was also no difference between the APL- 
positive and APL-negative patients with regard to 
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Table III. Procedure characteristics 
Characteristics APL-positive (n = 101) APL-negative (n = 225) p (Z 2) 
Indications: 
Limb salvage 89.2% 91.1% NS 
Claudication 10.8% 8.9% NS 
Procedure l vel:* 
Popliteal arteries 41.1% 33.7% NS 
Infrapopliteal rteries 58.9% 66.7% NS 
Conduits: 
Greater saphenous vein 66.7% 75.0% NS 
Alternate vein 29.4% 19.8% NS 
Prosthetic 3.9% 5.2% NS 
Complications 13.7% 18.6% NS 
Perioperative d ath 1.0% 2.2% NS 
Mean follow-up 19.4 mo 17.9 mo NS 
*Procedure l vel, site of distal anastomosis. 
indication for operation, procedure performed, con- 
duit used, and perioperative complications and deaths 
(Table III). 
The mean follow-up of APL-positive patients who 
underwent leg bypass procedures was 19.4 months 
(range, 0 to 58 months). For APL-negative patients, 
mean follow-up was 17.9 months (range, 0 to 64 
months) (p = NS ). Life- table 4-year primary patcncy, 
assisted primary patency, limb salvage, and survival 
rates for APL-positive patients were 43%, 72%, 79%, 
and 67%, respectively. For APL-negative patients, the 
4-year primary patency, assisted primary patency, limb 
salvage, and survival rates were 59%, 73%, 88%, and 
66%, respectively. By log-rank comparison of life 
tables, the difference in primary patency rates at 4 
years of 16% (APL-positive, 43%; APL-negative, 59%) 
was of borderline significance (p = 0.087). Compari- 
son of the life tables for assisted primary patency, limb 
salvage, and patient survival rates showed no differ- 
ence between the APL-positive and APL-negative 
patient groups (Tables IV to VII). During the fol- 
low-up period, 18.6% of bypass grafts in APL-positive 
patients required an average of 1.3 revisions to 
maintain assisted primary patency compared with 
11.1% of bypass grafts in APL-negative patients that 
required an average of 1.3 revisions (p = 0.097). 
Life-table comparison of patency rates, limb sal- 
vage rates, and survival rates between APL-positive 
patients who received warfarin therapy and those who 
did not receive warfarin showed statistically signifi- 
cant decreased 4-year primary patency rates in pa- 
tients who received warfarin therapy (34% vs 52%, 
p = 0.012). There was no statistically significant dif- 
ference, however, for assisted primary patency, limb 
salvage, and survival rates at 4 years between these two 
groups. APL-negative patients who received warfarin 
therapy compared with those who did not receive 
warfarin also had a significant decrease in primary 
patency rates (35% vs 66%, p < 0.05), assisted primary 
patency rates (51% vs 81%, p < 0.05), and limb salvage 
rates (79% vs 92%, p < 0.01). There was no difference 
in survival rate at 4 years. 
This comparison of bypass graft patency rates in 
APL-positive and APL-negative patients had an 85% 
power to detect a 20% or greater difference in graft 
patency rates at 5 years. This assumed a two-sided 
significance level of 0.05. 
DISCUSSION 
A previous cross-sectional study from our vascular 
surgery service stablished that APLs were present in 
a remarkable number of general vascular surgery 
patients (26.5%) and that this recognized hyperco- 
agulable state was strongly associated with a history of 
early occlusive failure of previously performed leg 
bypass procedures. 16The current study was therefore 
performed to determine whether infrainguinal bypass 
grafting procedures performed in patients who have 
APLs were associated with a prospectively determined 
inferior outcome compared with similar procedures 
performed in patients without APL. 
Surprisingly, there was minimal difference in out- 
come with regard to the primary patency rates and no 
difference in outcome with regard to assisted primary 
patency rates, limb salvage rates, or patient survival 
rates when procedures that were performed in pa- 
tients with and without APL were compared in this 
study. The small difference of 16% in the primary 
patency rate at 4 years (p = 0.087) and the similar 
difference ( 18.6% vs 11.1%, p = 0.097) in the need for 
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Table IV. Primary patency data of patients who underwent infrainguinal revascularization procedures 
Cumu~ve 
In~rval (m~ At risk Occluded Wi~drawn pa~n~ ra~ SEM 
APL-posifive 0 101 4 3 0.96 0.02 
6 94 13 14 0.82 0.04 
12 67 8 17 0.70 0.05 
24 42 3 16 0.64 0.06 
36 23 3 8 0.54 0.08 
48 12 2 4 0.43 0.09 
APL-negafive 0 225 14 15 0.94 0.02 
6 196 15 45 0.85 0.02 
12 136 10 35 0.78 0.03 
24 91 12 26 0.66 0.04 
36 53 0 10 0.66 0.05 
48 34 3 16 0.59 0.06 
p = 0.087 (log-rank test). 
Table V. Assisted primary patency data of patients who underwent infrainguinal 
revascularization procedures 
Cumulative 
Interval (too) At  risk Occluded Withdrawn patency rate SEM 
APL-positive 0 101 2 3 0.98 0.01 
6 96 5 16 0.92 0.03 
12 75 4 19 0.87 0.04 
24 52 2 19 0.83 0.05 
36 31 3 14 0.72 0.07 
48 14 0 5 0.72 0.10 
APL-negative 0 225 9 15 0.96 0.01 
6 201 11 47 0.90 0.02 
12 143 5 37 0.86 0.03 
24 101 7 34 0.79 0.04 
36 60 0 23 0.79 0.05 
48 37 2 20 0.73 0.06 
p = NS (log-rank test). 
revisions of bypass grafts in patients with and without 
APL was eliminated by successful graft surveillance 
and revision, as the assisted primary patency rate was 
essentially equal. 
Patency results of infrainguinal bypass grafting 
have been clearly shown to be affected by indications 
for operation, by conduit used, by site of distal 
anastomosis, by whether the operations are initial or 
reoperative procedures, and perhaps by the use of 
postoperative anticoagulation therapy. 19~22,24,25 in our 
study the APL-positive and APL-negative groups 
were well matched for each of these potential influ- 
ences on results with the exception of use of postop- 
erative anticoagulation, which was more frequent in 
the APL-positive group (Table II). It is therefore 
possible that the lack of a difference between the 
groups can be explained by the difference in use of 
anticoagulation with warfarin. This possibility seems 
distinctly unlikely because patients who were treated 
with warfarin demonstrated lower patency rates than 
those who were not treated with warfarin, both in the 
APL-positive and APL-negative groups. Although 
this difference may be caused by a number of factors, 
such as biased selection of patients who have a poorer 
prognosis for warfarin therapy, warfarin probably was 
not responsible for the lack of difference in patency 
results between the APL-positive and APL-negative 
groups. Because the use of warfarin was not random- 
ized, the exact influence cannot be determined with 
certainty. This study does not support he hypothesis 
that warfarin treatment was responsible for the lack of 
observed patency difference. Routine use of aspirin 
before and after surgery may also have contributed to 
decreased thrombotic events in the APL-positive 
group, but this hypothesis could not be determined 
because aspirin use was universal. 
Multiple previous reports have described patients 
who had APL and poor outcome of leg revasculariza- 
tion procedures. Ahn et al., 1° Eldrup-Jorgenson et 
al., 1~'12 Shortell et al., ~4 Nitecki et al., is and Ciocca et 
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Table VI.  Limb salvage data of  patients who underwent infrainguinal revascularization procedures 
Cumulative limb 
Interval (mo) At  r i sk  Ampulated Withdrawn salvage rate SEM 
APL-positive 0 101 2 2 0.98 0.01 
6 97 6 15 0.91 0.03 
12 76 1 21 0.90 0.03 
24 54 1 20 0.88 0.04 
36 33 1 15 0.85 0.06 
48 17 1 5 0.79 0.09 
APL-negative 0 225 3 13 0.99 0.01 
6 209 9 49 0.94 0.02 
12 151 3 41 0.92 0.02 
24 107 3 40 0.88 0.03 
36 64 0 24 0.88 0.04 
48 40 0 22 0.88 0.05 
p = NS (log-rank test). 
Table VI I .  Survival data of patients who underwent infrainguinal revascularization procedures 
Cumulative 
Interval (mo ) At  risk Dead Withdrawn survival rate SEM 
APL-positive 0 83 1 1 0.99 0.01 
6 81 3 11 0.95 0.02 
12 67 4 16 0.88 0.04 
24 47 4 21 0.79 0.05 
36 22 1 9 0.74 0.08 
48 12 1 3 0.67 0.11 
APL-negative 0 178 3 9 0.98 0.01 
6 166 10 36 0.92 0.02 
12 120 7 31 0.85 0.03 
24 82 1 34 0.84 0.04 
36 47 3 19 0.77 0.05 
48 25 3 11 0.66 0.08 
p = NS (log-rank test). 
al.,17 each described aseries of APL-positive patients, 
many of whom had poor outcome of leg procedures 
and APL. Of  course, none of these studies was 
prospective, and each relied on case-finding tech- 
n iques - that  is, only patients who had poor outcome 
were tested or the patients described were identified 
by reviewing records of patients who had test results 
that were positive for APL. Each of these authors 
concluded that APL-positive patients were at high risk 
for having a poor outcome of a revascularization 
procedure. The potential fallacy, of  course, is that 
without cross-sectional nd prospective studies, the 
case finding approach may inappropriately conclude 
that APL-positive patients are rare, and that they have 
a morbid prognosis. 
Our initial cross-sectional study demonstrated 
that APLs are, in fact, quite common in general 
vascular surgery patients (26.4%). 16 Our present pro- 
spective study demonstrates that the outcome of  leg 
grafting procedures performed in APL-positive pa- 
tients is minimally different or no different than 
when performed in APL-negative patients. Although 
the previous study found that APL was strongly 
associated with a history of previous graft failure, the 
prevalence of previous graft failure was very high in 
both groups in the present study (APL-posidve, 49%; 
APL-negative, 48%; p = NS; Table II), which reflects 
the rapidly changing nature of our referral practice 
in recent years toward reoperative surgery. 21 It is 
intriguing that APL may in part represent a result of 
vascular thrombotic events, rather than a cause. This 
finding would resolve the apparent contradiction 
that is posed by APL being associated with a history 
of graft failure, but not with prospectively deter- 
mined poorer outcome of leg grafting procedures. 
It is also possible that APLs have an adverse effect 
on the patency rates of prosthetic leg bypass grafts, 
as opposed to autogenous grafts. Many of the pre- 
viously failed grafts that were recorded in our pre- 
vious study were prosthetic. Almost none of the 
grafts that were observed prospectively in the current 
study were prosthetic. The present study does not 
JOURNAL OF VASCULAR SURGERY 
530 Lee et al. October 1996 
contain data to confirm or disprove either of these 
two speculations. 
In comparison with previous reports from our 
unit, the primary patency rate of grafting procedures 
performed in APL-positive patients in this study was 
low (43% at 4 years; Table IV). 19'22 This change was 
not a result of  the prevalence of APL, because the 
patency rate in APL-negative patients was similarly 
low (59% at 4 years; Table IV) when compared with 
the rates from previous reports. Rather, the decreas- 
ing primary patency rate of leg grafting procedures 
performed by our service in recent years reflects the 
increasing numbers of rcoperative procedures per- 
formed to tibial outflow tracts that required alternate 
vein conduits (Tables I I  and I I I) ,  all of  which are 
known to be associated with decreased primary pa- 
tency rates.19-22 The assisted primary patency rates of 
all bypass procedures remain acceptably high, which 
reflects the ongoing success of postoperative graft 
surveillance with duplex scans in detecting lesions that 
threaten graft patency and in permitting the elective 
repair of  these lesions before the occurrence of 
thrombosis of these high-risk grafts. 26 
It is possible that our present study included too 
few patients to detect a difference in the outcome of 
leg grafting procedures between APL-positive and 
APL-negative patients that in fact exists, which would 
be a type I I  statistical error. This study of 326 
procedures performed in 261 patients had 8 5% power 
to detect a difference of 20% or greater in the patency 
rate. The difference of 16% in the primary patency 
rates that was detected may be real (p = 0.087), but 
validation of a difference of this magnitude would 
require a larger study. 
This study describes results in patients who un- 
derwent urgent and elective surgery and in whom 
preoperative testing for hypercoagulable states was 
obtained prospectively. During the study period, 26 
patients underwent emergency surgery for acute 
thromboembolic events and were not included in the 
study because preoperative testing was not per- 
formed. It is possible that the prognosis for the 
APL-positivc study patients would have been worse if 
these emergency patients had been included. 
On the basis of this prospective study, we conclude 
that APL are found in a large number of patients who 
undergo leg bypass surgery in a university-based 
tertiary referral practice. There was minimal differ- 
ence in the outcome of the procedures that were 
performed in APL-positive patients compared with 
procedures performed in APL-negative patients with 
regard to morbidity and mortality rates, patency rates, 
limb salvage rates, and patient survival rates. The lack 
of difference in outcome was not a result of more 
frequent use of warfarin in APL-positive patients. The 
extreme morbidity and mortality rates that have been 
associated with APL in previous reports probably 
reflects case-finding techniques and is not confirmed 
by this prospective study. The presence of APL should 
not be regarded as a contraindication to proceeding 
with indicated leg revascularization procedures. 
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DISCUSSION 
Dr. D. Preston Flanigan (Orange, Calif.). This is a 
well-designed and properly conducted prospective study 
that looked at the risk of infrainguinal bypass failure in 
patients who had antiphospholipid antibodies compared 
with patients who did not have those antibodies. The 
statistical methods eem appropriate and the conclusions 
appear warranted. The results, however, are unexpected. 
Although a type II error would not seem likely, the 
possibility of flaws in the study design must be considered. 
Some factors that were not measured could have 
potentially put the control group at higher risk. For 
example, did you look at arteriographic runoffscores when 
comparing the two groups? Did you study platelet function 
or look for abnormal plasminogens in your patients? 
The presence of antiphospholipid antibodies was over- 
whelmingly the most prevalent coagulation abnormality 
you found. This finding is in contradistinction to numerous 
other studies, in which there has been more of a balance 
between the various types of coagulation abnormalities 
found. For example, in our study at the University of 
Illinois, platelet abnormalities were most prevalent but 
there were nearly equal incidences of protein C & S, 
antithrombin III, plasminogen, and antiphospholipid ab- 
0 normalities. African-Americans made up 50 ~ of our patient 
cohort. Did you look at the racial distribution in your 
patient groups? 
Did you look at the possibility of steroid use in your 
patients? It has been suggested that steroids probably 
ameliorate the autoimmune reaction and, therefore may 
blunt the hypercoagulation effect. 
You included all patients who had any type ofantiphos- 
pholipid antibody in the study group. It has been suggested 
that only patients who have IgG antiphospholipid antibod- 
ies show increased risk of thrombosis. Did you perform a 
separate analysis of those patients who had IgG antibodies? 
Did you evaluate the paticnts on the basis ofthc presence or 
the absence of thrombosis in other vascular beds? 
Although this study is appropriately performed and 
analyzed, the p value for the primary patency rate is close to 
significance, and the possibility of unaddrcssed confound- 
ing risk factors makes me unsure as to how to apply the 
results to current practice. I would certainly agree with the 
authors, however, that the presence of antiphospholipid 
antibodies i not a contraindication to leg revascularization. 
Do the authors believe that the incidence ofantiphos- 
pholipid antibodies i so high in peripheral vascular patients 
that we should perform routine screening? One might 
conclude from this study that screening isunnecessary, but 
it would probably identify ahigh percentage ofpatients who 
have antiphospholipid antibodies. My practice has been to 
treat all patients who are found to have antiphospholipid 
and other coagulation abnormalities with perioperative and 
postoperative anticoagulation. I  light of the current find- 
ings, what recommendations do the authors have for us 
regarding perioperative and postoperative anticoagulation 
in these patients? Is long-term anticoagulation indicated in 
these patients because of the risk of subsequent thrombosis 
in other vascular beds? 
The authors correctly point out that many previous 
studies that show higher graft failure rates suffer from 
selection bias. It is interesting also to note that most studies 
that suggest an increased risk of any type of thrombosis in 
patients who have antiphospholipid antibodies also suffer 
from selection bias. Using similar easoning, this fact would 
call into question the basic premise that patients who have 
antiphospholipid antibodies have an increased risk of any 
kind of thrombosis at all. Is the underlying premise wrong? 
It might be very important to observe these two groups of 
patients long-term to assess the incidence of any subsequent 
thrombotic events. 
JOURNAL OF VASCULAR SURGERY 
532 Lee et aL October 1996 
Dr. Raymond W. Lee. We did not look at arterio- 
graphic runoff scores for patients. None of our patients had 
platelet counts greater than 1 million/mm 3 or less than 
100,000/mm 3 before surgery. We did not study fibrinogen 
activity. 
Regarding the incidence ofantiphosphollpid antibodies 
detected in this population as compared with previous 
studies, our incidence of antiphospholipid antibodies de- 
tected in this whole 5-year group was similar to a cross- 
sectional study we performed. This incidence differs from 
that of the other study possibly because the tests for 
detection ofantiphospholipid antibodies were not identical. 
Also, we did not look at any racial factors, nor did we look 
at the use of steroids. 
It is believed that IgG is the most virulent of the type of 
antibodies that cause thrombosis, but IgA is also believed to 
cause thrombosis, and it is unclear whether IgM does or 
does not cause it. We do not have enough patients to stratify 
these three groups. 
The risks of previous leg thrombosis was similar be- 
tween both groups. About 50% of patients with and without 
antiphospholipid antibodies had previous thrombosis. 
Our policy has been to try and give warfarin to these 
patients who have antiphospholipid antibodies provided 
there is no contraindication and if they are willing to 
continue life-long follow-up with warfarin therapy. 
At this point we do recommend routine screening for 
antiphospholipid antibodies in our lower extremity popu- 
lation, and if the tests results are positive and there is no 
contraindication, we will give them warfarin. 
Dr. William C. Krupski (Denver, Colo.). With respect 
to lower extremity venous thrombosis it turns out that 
resistance to activated protein C, so-called factor V Leiden, 
is an important hypercoagulable state. Did you measure 
factor V Leiden in any of these patients and have you seen 
any arterial thrombosis associated with this disorder? 
Dr. Lee. We have started to look at resistance to 
activated protein C in the last year or so, but we do not have 
data on that yet. 
Dr. Victor M. Bernhard (Menlo Park, Calif.). It 
seemed that there was a significant increase in the frequency 
with which Coumadin was used in the patients who had the 
hypercoagulable states. Did you perform asubset analysis to 
determine whether that had any effect? If there was an effect 
and you had reevaluated the data after the Coumadin group 
was removed, you might have demonstrated a statistically 
significant difference. 
Dr. Lee. We actually performed a subset analysis on 
patients who received warfarin as compared with patients 
who did not in both groups. Patients with antiphospholipid 
antibodies who received warfarin did worse in terms of 
primary patency. Patients without antiphospholipid anti- 
bodies who received warfarin also did worse in terms of 
primary patency rates, assisted primary patency rates, and 
limb salvage rates. 
Dr. E. John Harris (Stanford, Cali£). I had one 
observation that I would like you to clarify. You only had 
49% of the patients who had antiphospholipid antibodies 
taking warfarin, and 24% of the patients in your control 
group took warfarin. Did those patients with antiphospho- 
lipid antibodies begin taking warfarin before they under- 
went surgery, or did they begin taking it afterward? You 
recommend chronic anticoagulation i  your conclusion, 
but it appears that less than 50% of your patients who had 
antiphospholipid antibodies were chronically anticoagu- 
lated. 
Dr. Lee. Actually, the decision to have patients take 
warfarin after surgery has changed over the last 5 years. We 
have become much more aggressive with treating patients 
with warfarin, and at the current ime our contraindications 
to warfarin therapy are decreasing. 
Dr. James Peck (Portland, Ore.). You gave us data 
about comparable coronary artery disease. Ninety percent 
of those patients with antiphospholipid antibodies had, in 
fact, anticardiolipin antibody. What percentage of each 
group had actual myocardial injury--that is, prior myocar- 
dial infarctions--that might explain the high incidence of 
anticardiolipin antibodies in your patients? 
Dr. Lee. We looked at symptomatic coronary artery 
disease, which means either previous myocardial infarction 
or unstable angina. I do not have the subgroup of patients 
who had myocardial infarction only separated in terms of 
coronary artery disease. 
Dr. David B. Roos (Denver, Colo.). You mentioned 
that the patients' Coumadin or warfarin treatment was 
given after surgery. Did you use any warfarin before surgery? 
I think that is the optimal time, like antibiotics, to correct 
the coagulation problem and cover the operative insult. It 
takes about 3 days, as you know, for warfarin to have its 
effect. There is no danger of operating on patients who are 
taking warfarin. I've been doing that for 34 years and have 
had no significant complications. Therefore, I think it 
would be more effective to start warfarin before surgery. 
Dr. Lee. That's an interesting thought. We give all of 
our patients aspirin before surgery, and during surgery they 
all received intravenous heparin. We have not been giving 
patients warfarin before surgery. 
Dr. D. Eugene Strandness, Jr. (Seattle, Wash.). I think 
this warfarin question is really an important one. I do not 
understand your reasoning as to why you would recom- 
mend that these patients should be put on a lifelong 
regimen of warfarin. How can you possibly justify that? 
Dr. John M. Porter. Well, that's not exactly the issue. 
The issue is that these people have all had failed previous 
bypass grafts and, we think that people who have had failed 
bypass grafts in general should be given warfarin with 
subsequent grafting procedures, both anticardiolipin-posi- 
tive and anticardiolipin-negative patients. We don't see a 
difference in how those two groups behave. 
Dr. Strandness. So everybody ought to be given 
warfarin? 
Dr. Porter. If they're undergoing a redo grafting 
procedure, not the primary grafting procedure. 
Dr. J. Dennis Baker (Los Angeles, Calif.). The fact that 
the primary and assisted primary patency curves are similar 
in the normal control patients and in the patients who had 
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thrombotic factor suggests that there is a problem with the 
conduit, not with the thrombotic process. Could you 
comment on these results? 
Dr. Porter. The p value is not significant between the 
two. Although there was a p value of 0.087, I'll take that as 
not significant. The conclusion of the paper is that we are 
now questioning the importance of an anticardiolipin 
antibody as a risk factor for hypercoagulation, a d we're not 
the first to question this. This has been questioned in the 
past 12 months in several medicine articles. 
It may be that the inclusion of an antiphospholipid 
antibody as a risk factor for hypercoagulation is an error. 
Maybe it's not a risk factor. Maybe it's a condition that 
comes and goes in response to infection or other things. Our 
conclusion is that currently we cannot find any great 
significance to this risk factor, and maybe it's not a risk factor 
at all. 
Dr. Anthony D. Whittemore (Boston, Mass.). I can't 
resist getting up, in spite of the number of discussants, 
having been responsible for raising this issue many years 
ago. During his fellowship, Dr. Alec Clowcs and I looked at 
the issue of vein graft failure and were unable to determine 
why 30% percent of those grafts failed. 
When we began to look for hypercoagulable states, we 
found that lupus anticoagulant and heparin-induced 
thrombocytopenia were the two variables associated with a 
higher incidence of early graft occlusion rate, and I would 
submit hat that observation still stands. 
You also measured lupus anticoagulant and only found 
positive results in two patients. Were either of those patients 
the ones who had early occlusions? Although we would 
agree with the conclusions that you have reached with 
regard to the APL, I 'm a bit concerned that some of the 
physicians in attendance may equate lupus anticoagulant 
and APL and then generalize your findings to all of the 
hypercoagulable states, and that is not what you're saying. 
Dr. Lee. Actually, lupus anticoagulated anticardiolipin 
antibodies are part of all antiphospholipid antibodies. 
Dr. Whittemore. Did you measure lupus anticoagulant 
by the Russell viper venom test? 
Dr. Lee. There are actually three different tests to detect 
the presence of lupus anticoagulants. 
Dr. Whittemore. I 'm still a little uncertain with regard 
to the influence of lupus anticoagulant on early graft 
patency. 
Dr. Lee. We don't have enough patients who have lupus 
anticoagulant only to perform a follow-up analysis on that 
factor. 
Dr. Roy L. Tawes, Jr. (Burlingame, Calif.). Is the 
consensus if we have a failed graft to put them all on 
Coumadin? That being the case, is it cost-effective to 
look for this sensitive marker, APL? What would you 
recommend? 
Dr. Porter. We're not prepared to make a recommen 
dation now. We're pointing out for the first time in vascular 
surgery circles that many people have antiphospholipid 
antibodies, and it does not seem to make much difference in 
how they get along. This is a preliminary report. We'll see if 
our findings are confirmed by other investigators. 
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